approved

Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis receives third FDA approval for oral Fabhalta (iptacopan) the first and only treatment approved in C3 glomerulopathy (C3G)

Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G)…

2 weeks ago

Antidoping rules approved for Milano Cortina 2026 and Dakar 2026

18 March 2025 - The International Olympic Committee (IOC) Executive Board (EB) today approved the Anti-Doping Rules applicable to the Olympic Winter Games Milano…

2 weeks ago
Simply Approved Mortgages Expands to the U.S., Bringing Consumer-First Mortgage SolutionsSimply Approved Mortgages Expands to the U.S., Bringing Consumer-First Mortgage Solutions

Simply Approved Mortgages Expands to the U.S., Bringing Consumer-First Mortgage Solutions

LOS ANGELES, CA, March 07, 2025 (GLOBE NEWSWIRE) -- Simply Approved Mortgages, a full-service mortgage brokerage dedicated to lowering costs…

4 weeks ago
Illuccix Approved in the United KingdomIlluccix Approved in the United Kingdom

Illuccix Approved in the United Kingdom

February 12, 2025 16:38 ET  | Source: Telix Pharmaceuticals Limited MELBOURNE, Australia, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals…

2 months ago
Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplantPress Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

Press Release: Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant

Sarclisa is the first anti-CD38 treatment approved in China for patients with newly diagnosed multiple myeloma ineligible for transplant  Approval…

2 months ago
OraQuick HIV Self-Test Now Approved for Use in AdolescentsOraQuick HIV Self-Test Now Approved for Use in Adolescents

OraQuick HIV Self-Test Now Approved for Use in Adolescents

January 07, 2025 07:05 ET  | Source: OraSure Technologies, Inc. BETHLEHEM, Pa., Jan. 07, 2025 (GLOBE NEWSWIRE) -- OraQuick® HIV…

3 months ago
ReCerf Hip Resurfacing Arthroplasty, from MatOrtho Becomes the World’s First All-Ceramic Hip Resurfacing Approved by a Regulatory AuthorityReCerf Hip Resurfacing Arthroplasty, from MatOrtho Becomes the World’s First All-Ceramic Hip Resurfacing Approved by a Regulatory Authority

ReCerf Hip Resurfacing Arthroplasty, from MatOrtho Becomes the World’s First All-Ceramic Hip Resurfacing Approved by a Regulatory Authority

Groundbreaking Innovation Receives TGA Approval in Australia LEATHERHEAD, England, Dec. 2, 2024 /PRNewswire/ -- MatOrtho, the UK-based global innovator of…

4 months ago
ReCerf Hip Resurfacing Arthroplasty, from MatOrtho Becomes the World’s First All-Ceramic Hip Resurfacing Approved by a Regulatory AuthorityReCerf Hip Resurfacing Arthroplasty, from MatOrtho Becomes the World’s First All-Ceramic Hip Resurfacing Approved by a Regulatory Authority

ReCerf Hip Resurfacing Arthroplasty, from MatOrtho Becomes the World’s First All-Ceramic Hip Resurfacing Approved by a Regulatory Authority

Groundbreaking Innovation Receives TGA Approval in Australia LEATHERHEAD, England, Dec. 2, 2024 /PRNewswire/ -- MatOrtho, the UK-based global innovator of…

4 months ago
ReCerf Hip Resurfacing Arthroplasty, from MatOrtho Becomes the World’s First All-Ceramic Hip Resurfacing Approved by a Regulatory AuthorityReCerf Hip Resurfacing Arthroplasty, from MatOrtho Becomes the World’s First All-Ceramic Hip Resurfacing Approved by a Regulatory Authority

ReCerf Hip Resurfacing Arthroplasty, from MatOrtho Becomes the World’s First All-Ceramic Hip Resurfacing Approved by a Regulatory Authority

Groundbreaking Innovation Receives TGA Approval in Australia LEATHERHEAD, England, Dec. 2, 2024 /PRNewswire/ -- MatOrtho, the UK-based global innovator of…

4 months ago
Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogsBoehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Boehringer Ingelheim launches VETMEDIN Solution (pimobendan oral solution), first oral solution approved by the FDA for congestive heart failure in dogs

Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in…

4 months ago
Show more Posts